Autoimmune diseases (AIDs) represent a significant challenge in the field of immunology, characterized by the immune system's failure to distinguish between self and non-self, leading to attacks on the body's own tissues. These diseases encompass a wide array of conditions, affecting millions globally, with a higher prevalence in females. Despite extensive research, the precise mechanisms that disrupt immune regulation remain elusive, and there is a pressing need for novel therapeutics that can effectively target the underlying causes of AIDs. Current treatments primarily focus on symptom management rather than addressing the root cause, often resulting in limited efficacy and undesirable side effects. Recent studies have highlighted the potential of antigen-specific therapies, which aim to restore immune balance by targeting specific self-antigens implicated in these diseases. However, the development and clinical application of such targeted immunotherapies are still in their nascent stages, necessitating further exploration and validation.
This research topic aims to explore the development and application of targeted immunotherapies for autoimmune diseases, with a focus on antigen-specific approaches. The primary objective is to investigate how these therapies can be harnessed to restore immune homeostasis and provide more effective treatment options for AIDs. Key questions include understanding the mechanisms by which these therapies can selectively target disease-specific antigens and evaluating their efficacy and safety in clinical settings. The research will also test hypotheses related to the potential of these therapies to alter disease progression and improve patient outcomes.
To gather further insights into the development of targeted immunotherapies for autoimmune diseases, we welcome articles addressing, but not limited to, the following themes:
- Antigen-specific vaccinations (DNA, peptide, protein)
- Tolerance induction by hyposensitization with antigen or peptide fragments
- Soluble peptide-MHC complexes
- CAR-T cells
- Monoclonal antibodies
- Elimination of self-antigen-specific lymphocytes
All manuscripts must be submitted directly to the section Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders, where they are peer-reviewed by the Associate and Review Editors of the specialty section. We welcome full-length research articles or reviews or single case studies followed by a literature review. See more info here: https://www.frontiersin.org/journals/immunology/sections/autoimmune-and-autoinflammatory-disorders-autoinflammatory-disorders/about#about-submission
The topic editors declare no conflict of interest
Autoimmune diseases (AIDs) represent a significant challenge in the field of immunology, characterized by the immune system's failure to distinguish between self and non-self, leading to attacks on the body's own tissues. These diseases encompass a wide array of conditions, affecting millions globally, with a higher prevalence in females. Despite extensive research, the precise mechanisms that disrupt immune regulation remain elusive, and there is a pressing need for novel therapeutics that can effectively target the underlying causes of AIDs. Current treatments primarily focus on symptom management rather than addressing the root cause, often resulting in limited efficacy and undesirable side effects. Recent studies have highlighted the potential of antigen-specific therapies, which aim to restore immune balance by targeting specific self-antigens implicated in these diseases. However, the development and clinical application of such targeted immunotherapies are still in their nascent stages, necessitating further exploration and validation.
This research topic aims to explore the development and application of targeted immunotherapies for autoimmune diseases, with a focus on antigen-specific approaches. The primary objective is to investigate how these therapies can be harnessed to restore immune homeostasis and provide more effective treatment options for AIDs. Key questions include understanding the mechanisms by which these therapies can selectively target disease-specific antigens and evaluating their efficacy and safety in clinical settings. The research will also test hypotheses related to the potential of these therapies to alter disease progression and improve patient outcomes.
To gather further insights into the development of targeted immunotherapies for autoimmune diseases, we welcome articles addressing, but not limited to, the following themes:
- Antigen-specific vaccinations (DNA, peptide, protein)
- Tolerance induction by hyposensitization with antigen or peptide fragments
- Soluble peptide-MHC complexes
- CAR-T cells
- Monoclonal antibodies
- Elimination of self-antigen-specific lymphocytes
All manuscripts must be submitted directly to the section Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders, where they are peer-reviewed by the Associate and Review Editors of the specialty section. We welcome full-length research articles or reviews or single case studies followed by a literature review. See more info here: https://www.frontiersin.org/journals/immunology/sections/autoimmune-and-autoinflammatory-disorders-autoinflammatory-disorders/about#about-submission
The topic editors declare no conflict of interest